Get started Log in

4974 — Takara Bio Share News

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Market Cap
¥138bn
Enterprise Value
¥128bn
Revenue
¥40bn

Japan's Takara Bio soars on gene therapy deal with Otsuka
10/04/2018 01:32
development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
09/04/2018 07:35
Table: Takara Bio - 9-MTH group results
30/01/2018 06:00
Table: Takara Bio - 6-MTH group results
07/11/2017 06:00
Table: Takara Bio Inc. -2017 6-month group forecast
24/10/2017 07:00
Brief: Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan
27/09/2017 07:49
Table: Takara Bio -Q1 group results
27/07/2017 07:00
Table: Takara Bio -2016/17 parent results
09/05/2017 07:00
Table: Takara Bio -2016/17 group results
09/05/2017 07:00
Brief: Takara Holdings' subsidiary Takara Bio says merger between US-based units
27/03/2017 07:19
Brief: Takara Holdings unit fully acquires WaferGen Bio-systems for $35.9 mln
01/03/2017 06:18
Brief: Wafergen Bio-Systems expects total revenue for Q4 2016 to be about $3.9 mln
15/02/2017 13:00
Table: Takara Bio -9-MTH group results
30/01/2017 06:00
Brief: Takara Bio to start phase I/II clinical trials of gene therapy for sarcoma treatment
24/01/2017 06:13
Brief: Takara Bio's unit completes acquisition of Rubicon Genomics
18/01/2017 01:54
Brief: Takara Bio unit to buy Rubicon Genomics
15/12/2016 06:27
Brief: Takara Bio signs exclusive license agreement of Oncolytic virus HF10 with Otsuka Pharmaceutical
15/12/2016 06:26
Brief: WaferGen Bio-Systems announces stockholder approval of merger with Takara Bio
15/11/2016 22:00
Table: Takara Bio -6-MTH group results
10/11/2016 03:20
Table: Takara Bio Inc. -2016 6-month group forecast
20/10/2016 07:00